230 related articles for article (PubMed ID: 23019074)
21. Is recurrent respiratory papillomatosis a manageable or curable disease?
Kim HT; Baizhumanova AS
Laryngoscope; 2016 Jun; 126(6):1359-64. PubMed ID: 26608928
[TBL] [Abstract][Full Text] [Related]
22. The predominant site of pharyngeal lesions in patients with recurrent respiratory papillomatosis.
Matsuzaki H; Asai R; Makiyama K
Eur Arch Otorhinolaryngol; 2022 Sep; 279(9):4461-4464. PubMed ID: 35503132
[TBL] [Abstract][Full Text] [Related]
23. Systemic bevacizumab for recurrent respiratory papillomatosis.
Baday YI; Ongkasuwan J; Venkatramani R
Int J Pediatr Otorhinolaryngol; 2020 Nov; 138():110352. PubMed ID: 32906078
[TBL] [Abstract][Full Text] [Related]
24. Use of intralesional cidofovir in the recurrent respiratory papillomatosis: a review of the literature.
Gazia F; Galletti B; Freni F; Bruno R; Sireci F; Galletti C; Meduri A; Galletti F
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):956-962. PubMed ID: 32017003
[TBL] [Abstract][Full Text] [Related]
25. [Clinical and molecular biology studies of respiratory papillomatosis].
Mahnke CG; Werner JA; Fröhlich O; Lippert BM; Hoffmann M; Rudert HH
Laryngorhinootologie; 1998 Mar; 77(3):157-64. PubMed ID: 9577823
[TBL] [Abstract][Full Text] [Related]
26. Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy.
Limsukon A; Susanto I; Soo Hoo GW; Dubinett SM; Batra RK
Chest; 2009 Sep; 136(3):924-926. PubMed ID: 19736197
[TBL] [Abstract][Full Text] [Related]
27. Novel human papilloma virus (HPV) genotypes in children with recurrent respiratory papillomatosis.
Mammas IN; Sourvinos G; Vakonaki E; Giamarelou P; Michael C; Spandidos DA
Eur J Pediatr; 2010 Aug; 169(8):1017-21. PubMed ID: 20213305
[TBL] [Abstract][Full Text] [Related]
28. The tumor microenvironment state associates with response to HPV therapeutic vaccination in patients with respiratory papillomatosis.
Norberg SM; Bai K; Sievers C; Robbins Y; Friedman J; Yang X; Kenyon M; Ward E; Schlom J; Gulley J; Lankford A; Semnani R; Sabzevari H; Brough DE; Allen CT
Sci Transl Med; 2023 Oct; 15(719):eadj0740. PubMed ID: 37878675
[TBL] [Abstract][Full Text] [Related]
29. Papillomavirus-specific CD4+ T cells exhibit reduced STAT-5 signaling and altered cytokine profiles in patients with recurrent respiratory papillomatosis.
James EA; DeVoti JA; Rosenthal DW; Hatam LJ; Steinberg BM; Abramson AL; Kwok WW; Bonagura VR
J Immunol; 2011 Jun; 186(11):6633-40. PubMed ID: 21531896
[TBL] [Abstract][Full Text] [Related]
30. A Th1/Th2-associated chemokine imbalance during infancy in children developing eczema, wheeze and sensitization.
Abrahamsson TR; Sandberg Abelius M; Forsberg A; Björkstén B; Jenmalm MC
Clin Exp Allergy; 2011 Dec; 41(12):1729-39. PubMed ID: 21801246
[TBL] [Abstract][Full Text] [Related]
31. Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis.
Robbins Y; Friedman J; Clavijo PE; Sievers C; Bai K; Donahue RN; Schlom J; Sinkoe A; Hinrichs CS; Allen C; Abdul Sater H; Gulley JL; Norberg S
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34462327
[TBL] [Abstract][Full Text] [Related]
32. Clinical course of recurrent respiratory papillomatosis: comparison between aggressiveness of human papillomavirus-6 and human papillomavirus-11.
Tjon Pian Gi RE; San Giorgi MR; Slagter-Menkema L; van Hemel BM; van der Laan BF; van den Heuvel ER; Dikkers FG; Schuuring EM
Head Neck; 2015 Nov; 37(11):1625-32. PubMed ID: 24955561
[TBL] [Abstract][Full Text] [Related]
33. Safety and Immunogenicity of a Nonadjuvant Human Papillomavirus Type 6 Virus-like Particle Vaccine in Recurrent Respiratory Papillomatosis.
Zhang CQ; Yi S; Liu XJ; Nan BY; Huang SY; Chen BB
J Voice; 2019 May; 33(3):363-369. PubMed ID: 30224308
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement.
So RJ; Hidalgo Lopez JC; Ballestas SA; Klein AM; Steuer C; Shin DM; Abousaud M; Teng Y; Saba NF; Tkaczuk AT; Schaefer ES; Seiwert TY; McClellan K; Best SR
Laryngoscope; 2024 Feb; 134(2):577-581. PubMed ID: 37470254
[TBL] [Abstract][Full Text] [Related]
35. [Clinical and molecular biology studies of laryngeal papillomatosis].
Mahnke CG; Werner JA; Fröhlich O; Lippert BM; Hoffman H; Rudert HH
Laryngorhinootologie; 1998 Jan; 77(1):27-33. PubMed ID: 9522309
[TBL] [Abstract][Full Text] [Related]
36. Molecular transformation of recurrent respiratory papillomatosis: viral typing and p53 overexpression.
Go C; Schwartz MR; Donovan DT
Ann Otol Rhinol Laryngol; 2003 Apr; 112(4):298-302. PubMed ID: 12731623
[TBL] [Abstract][Full Text] [Related]
37. Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis.
Rahbar R; Vargas SO; Folkman J; McGill TJ; Healy GB; Tan X; Brown LF
Ann Otol Rhinol Laryngol; 2005 Apr; 114(4):289-95. PubMed ID: 15895784
[TBL] [Abstract][Full Text] [Related]
38. Prevalence and clinical implications of low-risk human papillomavirus among patients with recurrent respiratory papillomatosis in Rio de Janeiro, Brazil.
Figueiredo MC; Justino MC; Delmonico L; Silvestre RT; de Castro TL; Dos Santos Moreira A; Macedo JMB; da Costa Carvalho MDG; Scherrer L; de Medeiros Lima DJM; Alves G; Ornellas MH
Auris Nasus Larynx; 2019 Aug; 46(4):570-575. PubMed ID: 30581074
[TBL] [Abstract][Full Text] [Related]
39. Parenteral Bevacizumab for the Treatment of Severe Respiratory Papillomatosis in an Adult Population.
Tkaczuk A; Trivedi S; Mody MD; Steuer CE; Shin DM; Klein AM; Saba NF
Laryngoscope; 2021 Mar; 131(3):E921-E928. PubMed ID: 33107615
[TBL] [Abstract][Full Text] [Related]
40. Immunological tolerance of low-risk HPV in recurrent respiratory papillomatosis.
Ivancic R; Iqbal H; deSilva B; Pan Q; Matrka L
Clin Exp Immunol; 2020 Feb; 199(2):131-142. PubMed ID: 31628850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
